LOTTE Holdings establishes a new Healthcare and Biopharmaceutical Corporate Venture Capital

TOKYO, August 29, 2024 /PRNewswire/ — LOTTE Holdings Co., Ltd. (“LOTTE Holdings”) is pleased to announce the establishment of a new Healthcare and Biopharmaceutical Corporate Venture Capital (“CVC”) focused on investments in biopharmaceuticals and next generation modalities.

LOTTE Group operates under the group philosophy of “enriching people’s lives by providing superior products and services that our customers love and trust.” LOTTE Group expanded its business into various fields and entered the healthcare and biopharmaceutical industries in 2022 by establishing LOTTE BIOLOGICS, a Contract Development and Manufacturing Organization (CDMO).